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Background: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic
models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and
mortality of stroke patients. IScore is a novel tool recently developed in order to predict mortality rates within
30 days and 1 year after ischemic stroke and diabetes is not included in the scoring scale of IScore. The aim of the
present study was to evaluate and compare IScore validity in ischemic stroke patients with and without diabetes.
Methods: This prospective study included 312 consecutive Caucasian patients with type 2 diabetes and 222
Caucasian patients without diabetes admitted for ischemic stroke in a tertiary Greek hospital. Thirty-day and 1-year
IScores were individually calculated for each patient and actual mortality was monitored at the same time intervals.
IScore’s predictive ability and calibration was evaluated and compared for ischemic stroke patients with and
without diabetes. The performance of IScore for predicting 30 and 1-year mortality between patients with and
without diabetes was assessed by determining the calibration and discrimination of the score. The area under the
receiver operating characteristic curve was used to evaluate the discriminative ability of IScore for patients with and
without diabetes, whereas the calibration of IScore was assessed by the Hosmer–Lemeshow goodness-of fit
statistic.
Results: Baseline population characteristics and mortality rates did not differ significantly for both cohorts. IScore
values were significantly higher for patients with diabetes at 30 days and 1 year after ischemic stroke and patients
with diabetes presented more frequently with lacunar strokes. Based on ROC curves analysis IScore’s predictive
ability for 30 day mortality was excellent, without statistically significant difference, for both cohorts. Predictive
ability for 1 year mortality was also excellent for both groups with significantly better ability for patients with
diabetes especially at high score values. Calibration of the model was good for both groups of patients.
Conclusions: IScore accurately predicts mortality in acute ischemic stroke Caucasian patients with and without
diabetes with higher efficacy in predicting 1 year mortality in patients with diabetes especially with high scores.
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Stroke is a leading cause of adult morbidity and mortality
worldwide [1,2] and diabetes constitutes a major risk fac-
tor for stroke [3-7]. Diabetes not only confers an increased
risk for stroke but is also connected with increased stroke
severity and mortality and poorer post-stroke functional
recovery [4,8-10]. In this context accurate evaluation of
early stroke prognosis in patients with diabetes, as well as
in stroke patients in general, is fundamental for guiding
interventions and establishing an evidence based health
care decision system.
IScore is a recently developed prognostic model by
Canadian Researchers for the prediction of 30-day and
1-year mortality after ischemic stroke (IS) that has not
been evaluated outside the Canadian Health Care System
[11,12]. Diagnosis of diabetes is not included in IScore pre-
diction model where only hyperglycemia upon admission is
taken into account. The aim of the present study was to
evaluate IScore validity in IS patients with diabetes and to
compare its efficacy with that in patients without diabetes.
Methods
Patients and methods
This prospective study was conducted in a tertiary Greek
hospital. The study population consisted of 312 consecutive
Caucasian patients with type 2 diabetes and 222 Caucasian
non-diabetic patients admitted between January 2008
and February 2011 for acute IS. Acute stroke was defined
according to the World Health Organization criteria [13]
and clinical diagnosis was confirmed by brain computed
tomography (CT). Categorization of IS subtypes was made
according to the Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) [14]. Comatose patients, patients
with hemorrhagic stroke, tumors, or other conditions
mimicking at presentation thrombotic stroke or transient
ischemic attacks were excluded from the study. The study
was approved by the Tzanion General Hospital Scientific
Board and Ethics Committee and informed consent was
obtained on all cases.
Thirty-day and 1-year scores were calculated for each
patient and actual mortality was monitored at the same
time intervals. Thirty-day and 1-year scores were calculated
independently and blinded to mortality data for each
patient by two neurology specialists (Table 1). Occurrence
of actual mortality was examined by telephone from a third
specialist blinded to IScore data. Missing or patients that
did not respond were categorized as lost to follow up.
IScore's mortality predictors (according to original
publication) included older age, male sex, stroke sever-
ity, non-lacunar stroke subtype, glucose ≥ 7.5 mmol/L
(135 mg/dL) upon admission, history of atrial fibrillation,
coronary artery disease (CAD), congestive heart failure
(CHF), cancer, dementia, kidney disease on dialysis and
dependency prior to stroke [11].Statistical analysis
Numerical variables were presented as mean ± standard
deviation, while discrete variables as absolute values and
summarized by percentages. Categorical variables were
analyzed using chi-square test or Fisher’s exact test.
To compare mean or, when appropriate, median differences
for continuous variables in baseline characteristics between
groups Student’s t-Test or Mann–Whitney U test were
used. The performance of IScore for predicting 30-days
and 1-year mortality between diabetic and non-diabetic
patients was assessed by determining the calibration and
discrimination of the score.
The area under the receiver operating characteristic
curve was used to evaluate the discriminative ability of
IScore for patients with and without diabetes. The area
under the curve (AUC) [15] was calculated as an index
of how well IScore could discriminate patients who
lived and those who died both in 30-day and 1-year
after admission. The discriminative power of the model
was considered excellent if the area under the receiver
operating characteristic curve was >0.80, very good if >0.75
and good if >0.70 [16].
The calibration of IScore was assessed by the Hosmer–
Lemeshow goodness-of fit statistic [17]. For the Hosmer–
Lemeshow statistic, the predicted risks of individual
patients were rank-ordered and divided into 8 risk cat-
egories based on quintiles according to initial IScore
publication [11]. Within each group of estimated risk,
the number of predicted deaths was accumulated against
the number of observed deaths and p > 0.05 was considered
to indicate acceptable calibration of the model. Baseline
characteristic analysis was performed using the IBM
SPSS for Windows v.20 software (IBM, New York, USA)
and ROC curve analysis was completed with STATAv12
(StataCorp LP, Texas, USA).
Results
Demographic baseline population characteristics (Table 1)
did not differ significantly between IS patients with diabetes
and patients without diabetes. Forty-five (14.4%, 95% CI,
0.11-0.18) patients with diabetes deceased 30 days after IS
and 86 (27.6%, 95% CI, 0.23-0.33) after 1 year and mortality
rates were similar for non-diabetic patients: 32 (14.4%, 95%
CI, 0.1-0.19) at 30 days and 55 (24.8%, 95% CI, 0.22-0.34) at
1 year. Mean IScore values at 30 days and 1 year were
185.3 ± 45.9 and 149.1 ± 22.1 respectively for patients with
diabetes and 139.1 ± 58.7 and 118.3 ± 43.6 for non-diabetic
patients and the above values were significantly higher in
patients with diabetes (Table 1). Regarding stroke subtypes
a statistically significant difference was observed between
groups with preponderance of lacunar strokes in IS patients
with diabetes (Table 1). Demographic population character-
istics and IScore variables are also presented after age strati-
fication (<65, 66-80 and >80 years old) in Table 2.
Table 1 Demographic baseline population characteristics and IScore variables at 30-days and 1-year
Variable Entire population Diabetic patients (n=312) Non diabetic patients (n=222) p-value
iScore 30 days 166,1 ± 56,3 185,3 ± 45,9 139,1 ± 58,7 <0,05#
iScore 1 year 136,3 ± 41 149,1 ± 22,6 118,3 ± 43,6 <0,05#
Age (mean±SD) 74,7 ± 6,6 75.03 ± 6.6 74.22 ± 6.5 0,222##
74 (69 - 82) 74 (69 - 80)
Gender n (%) 0,628*
Female 276 158 (50.6) 118 (53.2)
Male 258 154 (49.4) 104 (46.8)
Stroke severity (CNS) n (%) 0,247*
0 21 13 (4.2) 7 (3.2)
≤4 75 36 (11.5) 39 (17.6)
5-7 204 123 (39.4) 81 (36.5)
≥8 235 140 (44.9) 95 (42.8)
Stroke subtype n (%) <0,05*
Lacunar origin 244 168 (53.8) 76 (34.2)
Nonlacunar origin 219 102 (32.7) 117 (52.7)
Undetermined origin 71 42 (13.5) 29 (13.1)
Risk factor n (%) 0,304*
Atrial fibrillation 80 46 (14.7) 34 (15.3)
CHF 67 44 (14.1) 23 (10.4)
Previous MI 148 99 (31.7) 49 (22.1)
Current smoker 100 57 (18.3) 43 (19.4)
Comorbid condition n (%) 0,809**
Cancer 53 34 (10.9) 19 (8.6)
Renal dialysis 9 5 (1.6) 4 (1.8)
Preadmission disability n (%) 0,532*
Independent 435 254 (81.4) 181 (81.5)
Dependent n 99 58 (18.6) 41 (18.5)
Glucose on admission, mmol/L,dL n (%) <0,05*
<7.5 (<135) 295 159 (51) 136 (61.3)
≥7.5 (≥135) 239 153 (49) 86 (38.7)
Mortality rate n (%)
0,551*30 Day 77 45 (14.4) 32 (14.4)
1 Year 141 86 (27.6) 55 (24.8) 0,268*
SD indicates standard deviation; CNS: Canadian neurological scale; CHF: congestive heart failure; MI: myocardial infarction.
Statistical methods used: #Mann Whitney U test, ##t-Test, *Chi-square, **Fisher.
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building receiver operating characteristic (ROC) curves for
mortality both in diabetic and non-diabetic population for
30-day and 1 year mortality and the area under the curves
(AUC) was used to evaluate and compare the predictive
accuracy of risk classifications. Based on AUC analysis the
discriminative ability of IScore was excellent for patients
with diabetes with a value of 0.87 (95% CI, 0.80-0.93)
and patients without diabetes with a value of 0.85 (95% CI,
0.79-0.91) at 30 days without significant difference be-
tween groups (Chi = 0.17, p = 0.68) (Figure 1). Respectivelydiscriminative ability was also excellent for diabetic group
with a value of 0.93 (95% CI, 0.90-0.97) and non-diabetic
group with a value of 0.87 (95% CI, 0.82-0.91) at 1 year
with significantly higher discriminative ability (Chi = 5.23,
p < 0.05) for IS patients with diabetes especially located in
high risk (IScore >160) diabetic subgroups (Figure 1).
In order to evaluate the model’s validity on the basis
of its calibration, which represents the precision of the
probabilities generated by a prediction model, we tabulated
IScore categories and mortality in contingency tables. Using
Hosmer–Lemeshow goodness-of-fit test, which is the most
Table 2 Demographic baseline population characteristics and IScore variables at 30-days and 1-year for different age
groups (<65, 66-80 and >80 years old)
Age categories <65 66-80 >80
Mean ± SD Mean ± SD Mean ± SD
Age (years) 63,7 ± 1,2 72,3 ± 3,8 83,2 ± 2,3
iScore 30 days 120,6 ± 41,6 153,3 ± 46,4 207,9 ± 57,8
iScore 1 year 100,6 ± 28,4 126,0 ± 32,2 169,8 ± 41,8
Count (Row N %) Count (Row N %) Count (Row N %)
Sex Female 29 (10,5) 193 (69,9) 54 (19,6)
Male 8 (3,1) 157 (60,9) 93 (36,0)
CNS 0 No 37 (7,2) 345 (67,1) 132 (25,7)
Yes 0 (0,0) 5 (25,0) 15 (75,0)
CNS =<4 No 36 (7,8) 314 (68,4) 109 (23,7)
Yes 1 (1,3) 36 (48,0) 38 (50,7)
CNS 5-7 No 26 (7,9) 231 (70,0) 73 (22,1)
Yes 11 (5,4) 119 (58,3) 74 (36,3)
CNS >=8 No 12 (4,0) 160 (53,5) 127 (42,5)
Yes 25 (10,6) 190 (80,9) 20 (8,5)
Stroke subtype Lacunar origin 24 (9,8) 198 (81,1) 22 (9,0)
Nonlacunar origin 12 (5,5) 131 (59,8) 76 (34,7)
Underdetermined origin 1 (1,4) 21 (29,6) 49 (69,0)
Risk factor Atrial fibrillation 16 (20,0) 58 (72,5) 6 (7,5)
CHF 7 (10,4) 54 (80,6) 6 (9,0)
Previous MI 8 (5,4) 127 (85,8) 13 (8,8)
Current smoker 4 (4,0) 64 (64,0) 32 (32,0)
Current smoker No 30 (6,9) 292 (67,3) 112 (25,8)
Yes 7 (7,0) 58 (58,0) 35 (35,0)
Cancer No 36 (7,5) 334 (69,4) 111 (23,1)
Yes 1 (1,9) 16 (30,2) 36 (67,9)
Renal dialysis No 37 (7,0) 349 (66,5) 139 (26,5)
Yes 0 (0,0) 1 (11,1) 8 (88,9)
Dependent No 36 (8,3) 314 (72,2) 85 (19,5)
Yes 1 (1,0) 36 (36,4) 62 (62,6)
Glucose on admission above 135 No 25 (8,5) 218 (73,9) 52 (17,6)
Yes 12 (5,0) 132 (55,2) 95 (39,7)
Mortality 30 days No 37 (8,1) 338 (74,0) 82 (17,9)
Yes 0 (0,0) 12 (15,6) 65 (84,4)
Mortality 1 year No 34 (8,7) 311 (79,1) 48 (12,2)
Yes 3 (2,1) 39 (27,7) 99 (70,2)
SD indicates standard deviation; CHF: congestive heart failure; MI: myocardial infarction; CNS: Canadian neurological scale.
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[18], we compared the estimated predicted mortality from
the logistic regression models with the observed outcomes,
for each risk category, of IScore prediction model. The
Hosmer-Lemeshow test showed that the model’s calibration
was satisfactory both in diabetic (p = 0.18) and non-diabetic
population (p = 0.19).Discussion
Prognosis prediction after stroke is a field of intense
clinical research and several prognostic models have been
developed [19-22] towards this direction and among them
IScore has been proposed as a well validated tool for mor-
tality prediction [11,12]. Recently, IScore has also been
reported to reliably predict short term functional outcome
Figure 1 ROC curves for IScore regarding a) 30-day and b)
1-year actual mortality rates. Receiver operating characteristic (ROC)
curves for IScore regarding 30-day and 1-year actual mortality rates for
acute ischemic stroke diabetic (n = 312) and non diabetic patients
(n = 222). The area under the ROC curve was 0.87 (95% CI, 0.80-0.93)
for diabetic and 0.85 (95% CI, 0.79-0.91) for non-diabetic at 30 days and
0.93 (95% CI, 0.90-0.97) and 0.87 (95% CI, 0.82-0.91) at 1 year.
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acute IS as well as risk of hemorrhagic complications after
thrombolytic therapy [24] and the above are especially
important in the case of IS patients with diabetes given
the lower rates of favorable outcomes after thrombolytic
therapy observed in this group of stroke patients [25].
The development and broad application of a predictive
tool for stroke mortality and functional recovery is of
great importance today since it could identify patients at
increased risk, guide level of inpatient and outpatient
care and help neutralize health care disparities. Stroke is
considered a continuum today commencing before admis-
sion and continuing after discharge. Addressing risk factors,
improving quality of life and determining targeted interven-
tions and an evidence-based discharge plan are considered
fundamental factors determining outcome and reducing re-
hospitalization rates and morbidity and mortality [26,27].
In the present study we investigated the validity of
IScore in the prediction of 30-day and 1-year mortalityin IS patients with and without diabetes and our results
clearly indicate that IScore accurately predicts mortality in
both groups of IS patients. Additionally, according to our
findings, IScore’s predictive ability is higher in IS patients
with diabetes for 1 year mortality and this superiority is
specifically located at high risk subgroups.
Diabetes has been associated with increased risk of stroke
at a younger age and, not uniformly, with increased stroke
severity and mortality [4,8-10] as well as poorer favorable
outcomes after thrombolytic therapy [25] and in our cohort
patients with diabetes presented more frequently with lacu-
nar strokes and with more severe scores in the Canadian
Neurological Scale and higher IScores. Our results regard-
ing increased incidence of lacunar strokes in patients with
diabetes are in accordance with the findings of the majority
of studies [4,28-32] although there is not uniformity of
findings in all studies in this field [7].
Mortality rates after IS were similar for patients with
and without diabetes at 30 days and 1 year post stroke
in our study and the above are in accordance with the
findings of Camalesh et al who also reported similar
stroke mortality for patients with and without diabetes at
60 days and 1 year after IS [33] and Megherbi et al who
reported similar post stroke mortality IS patients with and
without diabetes at 3 months after IS [4]. Many studies
have reported increased stroke mortality in patients with
diabetes at different time points after ischemic stroke
[8,9,34-38] with the majority of studies with long term
follow up to report increased mortality. From the above it
can be inferred that diabetes seems to increase stroke
mortality on the long term while short term post stroke
mortality may be similar between IS patients with diabetes
and without diabetes and this is also in accordance with
the slower post stroke recovery and increased post stroke
disability reported for patients with diabetes [8,9].
This is the first study to evaluate IScore’s validity in
another population sample, outside Canada, and to
specifically examine validity in IS patients with diabetes.
Our study was also conducted in a merely Caucasian popu-
lation. Ethnicity has not been included as a parameter in
the initial publication of IScore presentation due to lack
of data for all patients although it was conferred from
the study loci that it has been conducted in a mainly
Caucasian population [11].
Race and ethnicity influence both incidence and progno-
sis of stroke with African Americans, Hispanic Americans
and American Indians/Alaska natives to be at increased risk
[39] while stroke mortality varies with African Americans
to consistently exhibit higher stroke mortality rates than
Caucasians [39,40] and this is attributed to increased stroke
severity, lower socioeconomic status, variations in risk
factors (uncontrolled blood pressure, smoking, inactivity,
diabetes), general lower life expectancy and lack of access
to medical care [39-41]. From the above point of view
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of great interest since it could unveil any peculiarities
or differences although it is expected to exert high validity.
Especially for African Americans, given the higher preva-
lence of risk factors and greater stroke severity, IScore is
expected, from the theoretical point of view and according
to our findings, to exhibit even higher than the hereby
reported validity.
The main weakness of the present study has been the
relatively small, although sufficient, population sample
(312 IS patients with diabetes and 222 without diabetes).
A larger population sample could have allowed us to
achieve even greater statistical power and this was more
obvious in the case of comorbid patient conditions where
we chose to report the results of Fisher’s exact test since
the expected values were relatively small.
Our results further support the broad use of IScore as a
tool for mortality prediction in IS stroke patients. IScore’s
validity in mortality prediction in IS patients with diabetes
is considered important given the explosive increase in
the incidence of type II diabetes [42], its close correlation
with stroke [43-45] as well as the increased stroke severity,
poorer prognosis and response to thrompolytic therapy in
IS patients with diabetes [25].
Conclusions
In conclusion, IScore exhibits excellent predictive accuracy
and good calibration in predicting 30 day and 1 year
mortality in type 2 diabetic and non-diabetic IS Caucasian
patients with even higher accuracy in predicting 1 year
post-stroke mortality in patients with type 2 diabetes
especially in high risk patients.
Abbreviations
IS: Ischemic stroke; CT: Computed tomography; TOAST: Trial of ORG 10172 in
acute stroke treatment; CAD: Coronary artery disease; CHF: Congestive heart
failure; ROC curves: Receiver operating characteristic curves; AUC: Area under
the curves; CNS: Canadian neurological scale; MI: Myocardial infarction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VD carried out part of the research, helped to draft the manuscript, and
performed the initial statistical report. KNT carried out the results evaluation,
helped to draft the manuscript, and participated in the design and
coordination of the study. GIP carried out part of the research, helped to
draft the manuscript, and participated in the design and coordination of the
study. KK performed the statistical analysis. EF carried out part of the
research. MV carried out part of the research. GE carried out part of the
research. NM carried out part of the research, and performed the data
collection. KTK carried out part of the research. AM conceived the protocol
design, and consulted to draft the manuscript. All authors read and
approved the final manuscript.
Author details
1Diabetes Center, “Tzanio” General Hospital of Piraeus, Piraeus, Greece.
2Department of Nursing, Faculty of Human Movement and Quality of Life
Science, University of Peloponnese, Sparta, Lakonia, Greece. 3Mathematics
Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
4Intensive Care Unit, “Papageorgiou” General Hospital of Thessaloniki,Thessaloniki, Greece. 51st Internal Medicine Department, “Tzanio” General
Hospital of Piraeus, Piraeus, Greece. 6Medical School, University of Ioannina,
Ioannina, Greece.
Received: 27 April 2013 Accepted: 28 August 2013
Published: 16 September 2013
References
1. Langhorne P, Coupar F, Pollock A: Motor recovery after stroke: a
systematic review. Lancet Neurol 2009, 8(8):741–754.
2. Kinlay S: Changes in stroke epidemiology, prevention and treatment.
Circulation 2011, 124(19):e494–e496.
3. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller
R, Ewing I, Moomaw CJ, Szaflarski JP, Gebel J, Shukla P, Broderick JP:
Epidemiology of ischemic stroke in patients with diabetes: the
greater Cincinnati/Northern Kentucky stroke study. Diabetes Care
2005, 28(2):355–359.
4. Megherbi SE, Milan C, Minier D, Courveur G, Osseby GV, Tilling K, Di Carlo A,
Inzitari D, Wolfe CD, Moreau T, Giroud M: Association between diabetes
and stroke subtype on survival and functional outcome 3 months after
stroke: data from the European BIOMED stroke project. Stroke 2003,
34(3):688–694.
5. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR:
UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK
prospective diabetes study risk engine. Stroke 2002, 33(7):1776–1781.
6. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L: Long-term risk factors
for stroke: twenty-eight years of follow-up of 7457 middle-aged men in
Goteborg, Sweden. Stroke 2006, 37(7):1663–1667.
7. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, Rexrode
KM: Prospective study of type 1 and type 2 diabetes and risk of stroke
subtypes: the nurses’ health study. Diabetes Care 2007, 30(7):1730–1735.
8. Sprafka JM, Virnig BA, Shahar E, McGovern PG: Trends in diabetes
prevalence among stroke patients and the effect of diabetes on stroke
survival: the Minnesota heart survey. Diabet Med 1994, 11(7):678–684.
9. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS: Stroke in patients with
diabetes. The Copenhagen stroke study. Stroke 1994, 25(10):1977–1984.
10. De Silva DA, Ebinger M, Christensen S, Parsons MW, Levi C, Butcher K,
Barber PA, Bladin C, Donnan GA, Davis SM: Baseline diabetic status and
admission blood glucose were poor prognostic factors in the EPITHET
trial. Cerebrovasc Dis 2010, 29(1):14–21.
11. Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, Tu JV, Mamdani M,
Austin PC: IScore: A risk score to predict death early after hospitalization for
an acute ischemic stroke. Circulation 2011, 123(7):739–749.
12. Bushnell C: Another score to predict ischemic stroke mortality?
Circulation 2011, 123(7):712–713.
13. Recommendations on stroke prevention, diagnosis and therapy. Report
of the WHO task force on stroke and other cerebrovascular disorders.
Stroke 1989, 20(10):1407–1431.
14. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh
EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for
use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute
stroke treatment. Stroke 1993, 24(1):35–41.
15. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver
operating characteristic (ROC) curve. Radiology 1982, 143(1):29–36.
16. Swets JA: Measuring the accuracy of diagnostic systems. Science 1988,
240(4857):1285–1293.
17. Hosmer DW, Taber S, Lemeshow S: The importance of assessing the fit
of logistic regression models: a case study. Am J Publ Health 1991,
81(12):1630–1635.
18. Hosmer DW, Lemeshow S: Assessing the fit of the model, applied logistic
regression. New York: Wiley; 1989:135–175.
19. Solberg OG, Dahl M, Mowinckel P, Stavem K: Derivation and validation of
a simple risk score for predicting 1-year mortality in stroke. J Neurol 2007,
254(10):1376–1383.
20. Johnston KC, Connors AF Jr, Wagner DP, Haley EC Jr: Predicting outcome
in ischemic stroke: external validation of predictive risk models.
Stroke 2003, 34(1):200–202.
21. Williams GR, Jiang JG: Development of an ischemic stroke survival score.
Stroke 2000, 31(10):2414–2420.
22. Smith EE, Shobha N, Dai D, Olson DM, Reeves MJ, Saver JL, Hernadez AF,
Peterson ED, Fonarow GC, Schwamm LH: Risk score for in-hospital
Dragoumanos et al. BMC Neurology 2013, 13:121 Page 7 of 7
http://www.biomedcentral.com/1471-2377/13/121ischemic stroke mortality derived and validated within the get with the
guidelines-stroke program. Circulation 2010, 122(15):1496–1504.
23. Saposnik G, Raptis S, Kapral MK, Liu Y, Tu JV, Mamdani M, Austin PC: The
iScore predicts poor functional outcomes early after hospitalization for
an acute ischemic stroke. Stroke 2011, 42(12):3421–3428.
24. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, Johnston CS:
The iScore predicts effectiveness of thrombolytic therapy for acute
ischemic stroke. Stroke 2012, 43(5):1315–1322.
25. Nikneshan D, Raptis R, Pongmoragot J, Zhou L, Johnston SC, Saposnik G:
Predicting clinical outcomes and response to thrombolysis in acute
stroke patients with diabetes. Diabetes Care 2013, 36(7):2041–2047.
26. Saposnik G, Kapral MK: Poststroke care: chronicles of a neglected battle.
Stroke 2007, 38(6):1727–1729.
27. Birbeck GL, Zingmond DS, Cui X, Vickrey BG: Multispecialty stroke services
in California hospitals are associated with reduced mortality.
Neurology 2006, 66(10):1527–1532.
28. Baliga BS, Weinberger J: Diabetes and stroke: part one–risk factors and
pathophysiology. Curr Cardiol Rep 2006, 8(1):23–28.
29. Licata G, Tuttolomondo A, Pinto A: Association between diabetes and
stroke subtype on survival and functional outcome 3 months after
stroke: data from the European BIOMED stroke project. Stroke 2004,
35(3):e61.
30. Tuttolomondo A, Pinto A, Salemi G, Di Raimondo D, Di Sciacca R, Fernandez
P, Ragonese P, Savettieri G, Licata G: Diabetic and non-diabetic subjects
with ischemic stroke: differences, subtype distribution and outcome.
Nutr Metab Cardiovasc Dis 2008, 18(2):152–157.
31. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH, Folsom AR:
Risk factors for ischemic stroke subtypes: the atherosclerosis risk in
communities study. Stroke 2006, 37(10):2493–2498.
32. Arboix A, Rivas A, Garcia-Eroles L, De Marcos L, Massons J, Oliveres M:
Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and
predictors of in-hospital mortality. BMC Neurol 2005, 5(1):9.
33. Kamalesh M, Shen J, Eckert GJ: Long term post-ischemic stroke
mortality in diabetes: a veteran cohort analysis. Stroke 2008,
39(10):2727–2731.
34. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL,
Morris AD, Waugh NR, Gatting W, Gale EA, Patterson CC, Qiao Z, Keen H:
Mortality from cerebrovascular disease in a cohort of 23000 patients
with insulin-treated diabetes. Stroke 2003, 34(2):418–421.
35. Olsson T, Viitanen M, Asplund K, Eriksson S, Hagg E: Prognosis after stroke
in diabetic patients. A controlled prospective study. Diabetologia 1990,
33(4):244–249.
36. Oppenheimer SM, Hoffbrand BI, Oswald GA, Yudkin JS: Diabetes mellitus
and early mortality from stroke. Br Med J 1985, 291(6501):1014–1015.
37. Oliveira TV, Gorz AM, Bittencourt PR: Diabetes mellitus as a prognostic
factor in ischemic cerebrovascular diseases. Arq Neuropsiquiatr 1988,
46(3):287–291.
38. Eriksson M, Carlberg B, Eliasson M: The disparity in long-term survival
after a first stroke in patients with and without diabetes persists: the
Northern Sweden MONICA study. Cerebrovasc Dis 2012, 34(2):153–160.
39. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB,
Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM,
Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,
Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS,
Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, et al:
Heart disease and stroke statistics – 2012 update: a report from the
American heart association. Circulation 2012, 125(1):e2–e220.
40. Gillum RF: Stroke mortality in blacks: disturbing trends. Stroke 1999,
30(8):1711–1715.
41. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffith P, Gorelick PB,
Howard G, Leira EC, Morgenstern LB, Ovbiagele B, Peterson E, Rosamond
W, Trimble B, Valderrama AL: Racial-ethnic disparities in stroke care:
the American experience: a statement for healthcare professionals
from the American heart association/American stroke Association.
Stroke 2011, 42(7):2091–2116.
42. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025:
prevalence, numerical estimates and projections. Diabetes Care 1998,
21(9):1414–1431.
43. Towfighi A, Markovic D, Ovbiagele B: Current national patterns of
comorbid diabetes among acute ischemic stroke patients. Cerebrovasc
Dis 2012, 33(5):411–418.44. Venketasubramanian N, Rother J, Bhatt DL, Pasquet B, Mas JL, Alberts MJ,
Hill MD, Aichner F, Steg PG: Two-year vascular event rates in patients
with symptomatic cerebrovascular disease: the REACH registry.
Cerebrovasc Dis 2011, 32(3):254–260.
45. Lees KR, Walters MR: Acute stroke and diabetes. Cerebrovasc Dis 2005,
20(Suppl 1):9–14.
doi:10.1186/1471-2377-13-121
Cite this article as: Dragoumanos et al.: Evaluation of IScore validity in a
Greek cohort of patients with type 2 diabetes. BMC Neurology
2013 13:121.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
